RenaSci

Metabolic Consequences of Antipsychotic Therapy

19/11/2012

RenaSci's experts contribute chapter on the metabolic consequences of antipsychotic therapy to a new book on current antipsychotics. Our review describes the effects of antipsychotics on various metabolic risk factors including body weight, adiposity and glycaemic control; critically evaluates animal models of these serious adverse effects and discusses various strategies to mitigate the weight gain and other metabolic actions of repeated antipsychotic administration. The full details of the book chapter are :-

Heal DJ, Gosden J, Jackson HC, Cheetham SC and Smith SL. 'Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity' in 'Current Antipsychotics', Handbook of Experimental Pharmacology Vol 212, G. Gross and MA Geyer (Ed), Springer, pp 135-164, 2012.

Please contact us for further information on this topic or about our animal model of antipsychotic-induced weight gain.

Special Issue of Neuropharmacology on 'Central Regulation of Food Intake and Energy Expenditure'

19/06/2012

RenaSci's experts (David J Heal, Sharon L Smith and Robert B Jones) have recently edited a Special Issue of Neuropharmacology which includes 11 review articles and 3 original research reports on the topic of Central Regulation of Food Intake and Energy Expenditure (Volume 63, Issue 1, pages 1-68, July 2012, Elsevier). The Special Issue describes recent advances in our knowledge of the highly complex mechanisms underlying the control of food consumption and energy output and reviews potential new molecular targets for the development of antiobesity drugs. In addition to the editorial, we have contributed two review articles :-

Animal models to explore the effects of CNS drugs on food intake and energy expenditure. Steven P Vickers and Peter G Clifton. pages 124-131.

What is the prognosis for new centrally-acting antiobesity drugs? David J Heal, Jane Gosden and Sharon L Smith. pages 132-146.

The contents of this Special Issue of Neuropharmacology, which provides a comprehensive review of recent preclinical and clinical antiobesity research, can be viewed by clicking here.

Biologics for Testing?

25/05/2012

Biologics are protein-based therapeutics that are biotechnologically-produced or isolated from living sources and include, for example, monoclonal antibodies and vaccines. Biologics have complex structures compared to conventional chemically-synthesised drugs and generally have to be given parenterally. Our staff can administer biologics intraveneously and can infuse peptides from subcutaneously-implanted osmotic minipumps. We have experience of giving monoclonal antibodies and vaccines acuely and chronically to rodents and can take a variety of blood, CSF fluid and tissue samples for further analysis. If you would like us to evaluate your biologic products in any of our models please contact us.

RenaSci Review on the Neuropharmacology of ADHD Drugs Selected  for Special Issue of Neuropharmacology

30/04/2012

A review by our experts 'The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety' Neuropharmacology 57: 608-618, 2009 (DJ Heal, SC Cheetham and SL Smith) has recently been chosen for a Virtual Special Issue on Cognitive Enhancers that draws together a selection of outstanding contributions on the topic published in Neuropharmacology over the last few years.